Activist Shareholder Sues ProQR, Demands Board Investigation and Independent Director
PRQR sits 30% above its 52-week low of $1.33 on light trading volume (0.3× avg).
Summary
Activist investor Van Herk Investments, holding 10.9% of ProQR, has filed a legal petition with the Amsterdam Court of Appeal, seeking an investigation into alleged systematic governance failures and mismanagement, and demanding the immediate appointment of an independent non-executive director.
Key Events · Ownership and Investor Activity · PRQR
-
Legal Petition Filed Against ProQR
Activist investor Van Herk Investments (10.9% stake) has filed a petition with the Enterprise Chamber of the Amsterdam Court of Appeal, requesting an investigation into ProQR's policies and conduct since May 2024.
-
Allegations of Governance Failures
The petition cites systematic deviations from governance frameworks, including improper director reappointments (e.g., James Shannon exceeding term limits), lack of independent oversight, and self-serving compensation practices.
-
Demand for Independent Director
Van Herk requests the immediate appointment of an independent non-executive director to the board as a relief measure, aiming to restore internal order and strengthen oversight.
-
Concerns Over Dilutive Offering
The filing highlights a recent capital issuance where Van Herk was not offered pro rata participation, while strategic partner Eli Lilly was, further diluting Van Herk's stake and raising concerns about fair treatment of shareholders.
Analysis · PRQR · Life Sciences
Activist investor Van Herk Investments, a 10.9% shareholder, has escalated its dispute with ProQR by filing a legal petition with the Amsterdam Court of Appeal. This action seeks a formal investigation into alleged systematic governance failures, including improper director reappointments, lack of independent oversight, and disproportionate executive compensation. The petition also demands the immediate appointment of an independent non-executive director, representing a significant challenge to the company's current leadership and corporate governance structure. This legal intervention could force substantial changes to ProQR's board and operational policies.
At the time of this filing, PRQR was trading at $1.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $238.9M. The 52-week trading range was $1.33 to $3.10. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.